此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

葡萄糖依赖性胰岛素多肽:对骨重塑和细胞活性的影响(Ginebra) (GINEBRA)

Glucose-dependent insulinotropic polypeptide (GIP) is released by the intestines in response to food intake and increases insulin secretion. Although short-term (< 3 hours) stimulation with GIP decreases bone resorption in humans, the effect may vanish following continuous administration within 24 hours, at least in patients with type 1 diabetes. Whether the anti-resorptive effect of GIP can be maintained if the hormone is non-continuously administrated is unclear. As the first GIP receptor (GIPR) agonist, tirzepatide was recently approved for the treatment of obesity and type 2 diabetes in the USA and type 2 diabetes alone in the EU, there is a need to establish knowledge about the long-term effects of GIP on bone health, including if different exposure times to GIP have different skeletal effects.

This project will investigate whether GIP maintains its anti-resorptive potential if given as intermittent compared to continuous infusion in healthy men and women aged 18-40 years. Administration cycles involve intermittent (8 hours daily) and continuous (24 hours daily) injection of GIP for three days each. The effect of GIP will be measured by bone markers in blood samples, as well as in vitro activity and genetic alterations of bone cells (osteoclasts and osteoblasts) using bone marrow aspirates and bone marrow biopsies. Each participant will receive both administration cycles using a crossover design with a 14-28 days washout period between administrations of GIP.

研究概览

研究类型

介入性

注册 (实际的)

13

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Esbjerg、丹麦、6700
        • University hospital of Southern Denmark

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 40年 (成人)

接受健康志愿者

是的

有资格学习的性别

全部

描述

Inclusion Criteria:

  • healthy volunteers

Exclusion Criteria:

  • pre-diabetes or diabetes (HbA1c >42mmol/mol)
  • BMI >28
  • fractures with < 6months
  • comorbidities/treatments that may influence bone metabolism or procedures - -- pregnancy
  • inability to provide informed concent

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:基础科学
  • 分配:随机化
  • 介入模型:交叉作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Intermittent then continious

The participants that recive the intermittent administration first, followed by the continious

Recombinant human GIP (1-42)

实验性的:Continious then intermittent

The participants that recives the continious administration first, follwoed by the intermittent

Recombinant human GIP (1-42)

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Serum levels of CTX
大体时间:During a three day period. With 14-28 days of washout between the two administration methods

Serum levels of CTX (bone resorption marker) will be measured prior to, during, and at after the intervention, with both administration methods (continious and intermittent)

During a three day period. With 14-28 days of washout between the two administration methods

次要结果测量

结果测量
措施说明
大体时间
Serum levels of osteocalcin and P1NP
大体时间:During a three day period. With 14-28 days of washout between the two administration methods

Serum levels of osteocalcin and P1NP (bone formation markers) will be measured prior to, during, and at after the intervention, with both administration methods (continious and intermittent)

During a three day period. With 14-28 days of washout between the two administration methods
Serum levels of GIP
大体时间:During a three day period. With 14-28 days of washout between the two administration methods

Serum levels of GIP will be measured prior to, during, and at after the intervention, with both administration methods (continious and intermittent)

During a three day period. With 14-28 days of washout between the two administration methods

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2025年11月10日

初级完成 (实际的)

2026年9月17日

研究完成 (实际的)

2026年9月17日

研究注册日期

首次提交

2025年1月17日

首先提交符合 QC 标准的

2025年1月17日

首次发布 (实际的)

2025年1月24日

研究记录更新

最后更新发布 (实际的)

2026年10月1日

上次提交的符合 QC 标准的更新

2026年9月30日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

IPD 计划说明

individual participant data will not be shared following GDPR and local data mangament regulation. However data(anonymous) and results will be published once the study is completed.

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅